MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Intra-Cellular Therapies Inc

Geschlossen

BrancheGesundheitswesen

131.89 -0.02

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

131.89

Max

131.89

Schlüsselkennzahlen

By Trading Economics

Einkommen

9.4M

-17M

Verkäufe

24M

199M

EPS

-0.16

Gewinnspanne

-8.475

Angestellte

860

EBITDA

9.8M

-29M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-0.79% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.8B

14B

Vorheriger Eröffnungskurs

131.91

Vorheriger Schlusskurs

131.89

Nachrichtenstimmung

By Acuity

40%

60%

126 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Intra-Cellular Therapies Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Jan. 2025, 12:11 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13. Jan. 2025, 11:40 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22. Jan. 2025, 14:09 UTC

Top News
Ergebnisse

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22. Jan. 2025, 11:22 UTC

Top News
Ergebnisse

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13. Jan. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13. Jan. 2025, 20:12 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13. Jan. 2025, 16:18 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13. Jan. 2025, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13. Jan. 2025, 14:10 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13. Jan. 2025, 12:25 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13. Jan. 2025, 11:57 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13. Jan. 2025, 11:56 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13. Jan. 2025, 11:45 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13. Jan. 2025, 11:43 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13. Jan. 2025, 11:43 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13. Jan. 2025, 11:42 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13. Jan. 2025, 11:41 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13. Jan. 2025, 11:40 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13. Jan. 2025, 11:34 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13. Jan. 2025, 11:32 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13. Jan. 2025, 11:32 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13. Jan. 2025, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13. Jan. 2025, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13. Jan. 2025, 11:30 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13. Jan. 2025, 10:55 UTC

Akquisitionen, Fusionen, Übernahmen

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13. Jan. 2025, 10:41 UTC

Akquisitionen, Fusionen, Übernahmen

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Peer-Vergleich

Kursveränderung

Intra-Cellular Therapies Inc Prognose

Kursziel

By TipRanks

-0.79% Nachteil

12-Monats-Prognose

Durchschnitt 130.83 USD  -0.79%

Hoch 132 USD

Tief 118 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Intra-Cellular Therapies Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

4

Buy

9

Halten

0

Sell

Technischer Score

By Trading Central

131.5 / 131.92Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

No Evidence

Langfristig

No Evidence

Stimmung

By Acuity

126 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.